Ildong Pharmaceutical Publishes "2026 Sustainability Management Report"
Ildong Pharmaceutical announced on June 5 that it has published its "2026 Sustainability Management Report," outlining the company’s ESG (Environmental, Social, and Governance) management status and direction under the vision of "Realizing a Sustainable Healthcare Company Creating Social Value."
The company explained that the report was published to share and actively communicate key activities, achievements, and mid- to long-term strategies related to ESG management—including environmental, social, and governance areas—with stakeholders.
Ildong Pharmaceutical Publishes 2026 Sustainability Management Report. Ildong Pharmaceutical
View original imageThis report covers the period from January to December of the previous year and is structured around Ildong Pharmaceutical’s ▲ ESG management system and achievements ▲ ESG management status by field—such as environment, social, and governance—and ▲ relevant data and appendices.
Additionally, the report systematizes the company’s activities, achievements, and mid- to long-term implementation plans regarding five core issues identified through a materiality assessment: ▲ securing future growth engines ▲ securing talent and strengthening human resource capabilities ▲ improving product quality and safety management ▲ reducing waste and promoting resource circulation ▲ reinforcing anti-corruption compliance.
Last year, Ildong Pharmaceutical focused on enhancing sustainability by improving corporate indicators and profitability based on management efficiency efforts. The company also fostered employee pride and a sense of community through the establishment of "Dongnyeok Hall," a promotional space showcasing the company’s history.
In the environmental sector, the company completed the development of a "company-wide environmental indicator management system," further advancing its environmental management framework. To address climate and energy issues, it expanded solar power facilities at its business sites and achieved a waste recycling rate of over 70%.
In the social sector, Ildong Pharmaceutical emphasized sharing mutual value with internal and external stakeholders and strengthening partnerships through initiatives such as ▲ fostering a healthy corporate culture ▲ ensuring safety and health management ▲ expanding the scope of human rights impact assessments ▲ building mutually beneficial relationships with partners ▲ contributing to local communities.
For governance, the focus was on emphasizing the functions and responsibilities of the board of directors and enhancing shareholder value. The company increased its compliance rate with the key indicators of the "Corporate Governance Report" disclosure, as suggested by the Korea Exchange, by 60 percentage points compared to the previous year, and accelerated the establishment of an integrated company-wide risk management system.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Ildong Pharmaceutical stated that it will continue to expand and advance its ESG management to effectively respond to market conditions and risk factors, meet stakeholder expectations, and lay the foundation for becoming a sustainable company with a virtuous business cycle.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.